AMN107 has potent activity in leukemia resistant to Gleevec
Researchers found marked improvement in chronic myeloid leukemia and acute lymphocytic leukemia patients treated with AMN107. The drug, taken in pill form, outperforms Gleevec by up to 50 times in shutting down cancer-causing tyrosine kinase.